Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes

US9115357B2 · kind B2 · utility

Assignees

• Baxter International Inc. · US
• Baxter Healthcare SA · CH
• University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

• Larry R. Brown · Newton, US
• Vered Bisker-Leib · Woburn, US
• Terrence L. Scott · Winchester, US
• Debra Lafreniere · Dighton, US
• Jennifer Machen · Export, US
• Nick Giannoukakis · Pittsburgh, US

Key dates

• Filing date: Jun 24, 2010
• Grant date: Aug 25, 2015
• Expiry date: Dec 13, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.